Cognitive Non-Pharmacological

Abdulhadi E., Ireland D., Simpson R., Morrow S.A., Le E., Donkers S., Knox K.B. on behalf of the MSBEST Team. (2022). Cognitive Impairment: Non-pharmacological Rehabilitation Interventions. Multiple Sclerosis Best Evidence-Based Strategies and Treatment/Therapies for Rehabilitation. Version 1.0: p 1-219.

PDF of Module

Podcast Summary

Author Disclosures

Dr. Sarah Donkers has received research funding from the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Branch Out Neurological Foundation, Praxis Spinal Cord Institute, Craig Neilson Foundation, Saskatchewan Health Research Foundation, Saskatchewan Centre for Patient-Oriented Research, College of Medicine University of Saskatchewan, Saskatchewan Ministry of Health, Heart and Stroke Saskatchewan, Spinal Cord Injury Saskatchewan and Saskatoon City Hospital Foundation. She has received investigator-initiated research funds from Helius Medical Technologies, and program funding from the Multiple Sclerosis Society of Canada for the NeuroSask Active and Connected Program.

Dr. Katherine Knox has received research funding from the Multiple Sclerosis Society of Canada, Saskatchewan Health Research Foundation, Saskatchewan Centre for Patient-oriented Research, Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch, College of Medicine University of Saskatchewan, and Saskatoon City Hospital foundation. She is the director for the Saskatchewan MS Drugs Research Program Quality of Life and Health Outcomes Study, is a member of the Saskatchewan MS Drugs Program Panel, was involved in a Roche sponsored clinical trial as a site investigator and received program funding from the Multiple Sclerosis Society of Canada for the NeuroSask Active and Connected Program.

Dr. Sarah Morrow has served on advisory boards for Biogen Idec, Celgene, EMD Serono, Novartis, Roche, Sanofi Genzyme, and Teva Neurosciences. She has received investigator-initiated grant funds from Biogen Idec, Novartis, Roche, and Sanofi Genzyme and has acted as site primary investigator for multicenter trials funded by AbbVie, Celgene, EMD Serono, Novartis, Roche, and Sanofi Genzyme. She has received research funding from the Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, and Canadian Institutes of Health Research.

Dr. Robert Simpson has received funding from the Canadian Institutes for Health Research for an integrated knowledge translation grant studying mindfulness for people with multiple sclerosis.

Eman Abdulhadi, Devon Ireland and Dr. Emma Le have no disclosures.